journal contribution posted on 2023-04-03, 18:43 authored by Tomomi M. Yamamoto, Patricia G. Webb, Dana M. Davis, Heidi K. Baumgartner, Elizabeth R. Woodruff, Saketh R. Guntupalli, Margaret Neville, Kian Behbakht, Benjamin G. Bitler
Supplementary Figure from Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors
Department of Defense
Rocky Mountain Neurological Disorders Core
Diabetes Research Center
National Institute of Diabetes and Digestive and Kidney DiseasesFind out more...
University of Colorado Cancer Center
ARTICLE ABSTRACTHigh-grade serous ovarian cancer is the deadliest gynecologic malignancy due to progression to resistant disease. Claudin-4 is classically defined as a tight junction protein and is often associated with epithelial cancers. Claudin-4 is aberrantly expressed in nearly 70% of all ovarian cancer tumors and conveys a worse overall prognosis. Elevated claudin-4 expression correlates to increased DNA repair activity and resistance to DNA damaging agents. PARP inhibitors are emerging as an effective therapeutic option for patients with ovarian cancer and function by promoting DNA damage. The study examines the relationship between claudin-4 expression and the response to PARP inhibitors using both genetic and pharmacologic inhibition of claudin-4 in in vitro and ex vivo models of ovarian cancer to examine DNA repair markers and functional activity. Genetic inhibition of claudin-4 results in the downregulation of several DNA damage repair effectors, including 53BP1 and XRCC1. Claudin-4 knockdown did not change homology-directed repair but inhibited nonhomologous end-joining and reduced 53BP1 foci formation. In 15 primary ovarian cancer tumors, higher claudin-4 expression significantly correlated to a dampened PARP inhibitor-mediated antiproliferation response. Further, claudin-4 inhibition in high claudin-4 tumors sensitized tumor sections to PARP inhibition. These data highlight that claudin-4 expression in ovarian cancer tumors could serve as both a marker of PARP inhibitor response and a therapeutic target to improve PARP inhibitor response.